Alessandra Mangia.

Eric Lawitz, M.D., Alessandra Mangia, M .D., David Wyles, M.D., Maribel Rodriguez-Torres, M.D., Tarek Hassanein, M.D., Stuart C. Gordon, M.D., Michael Schultz, M.D., Ph.D., Mitchell N. Davis, D.O., Zeid Kayali, M.D., K. Rajender Reddy, M.D., Ira M. Jacobson, M.D., Kris V. Kowdley, M.D., Lisa Nyberg, M.D., G. Mani Subramanian, M.D., Ph.D., Robert H. Hyland, D.Phil., Sarah Arterburn, M.S., Deyuan Jiang, Ph.D., John McNally, Ph.D., Diana Brainard, M.D., William T. Symonds, Pharm.D., John G.

Randomization Eligible infants were randomly designated in a 1:1 ratio to receive either palivizumab or placebo during the winter season . The blinding of study-group assignment was performed with a randomization list that used a permuted-block design, that was generated by an independent pharmacist before the start of the trial. The randomization was stratified regarding to gestational age group. Blinding was achieved with the use of a placebo complementing the reconstituted palivizumab remedy. The researchers who received the logs and performed the analyses and the parents had been unaware of study-group assignments until 12 months of follow-up was finished for all participants. The study nurses who administered the analysis drugs were alert to study-group assignments because it was not really feasible to prepare and administer the procedure in a blinded fashion within 3 hours after reconstitution.